Led by cancer research pioneers, MEKanistic is advancing a novel class of selective kinase inhibitors rationally designed to target both EGFR and PI3K with a single molecule. This breakthrough design expands the therapeutic window by inhibiting compensatory resistance pathways at the same time, avoiding inherent toxicity challenges of multi-compound treatments.
Company Details
- Employees
- 7
- Founded
- -
- Address
- 1015 Glenwood Ave, Minneapolis,minnesota 55405,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.mekanistic.com
- HQ
- Minneapolis, Minnesota
Mekanistic Therapeutics Questions
Mekanistic Therapeutics's website is http://www.mekanistic.com
Mekanistic Therapeutics's LinkedIn profile is https://www.linkedin.com/company/mekanistic-therapeutics
Mekanistic Therapeutics has
7 employees.
View email and phone details for 7
employees at Mekanistic Therapeutics.
Mekanistic Therapeutics's industry is
Biotechnology Research
Mekanistic Therapeutics's top competitors are
Ttc Oncology,
Luminary Therapeutics, Inc,
Tychon Biosciences,
Celcuity,
Oneome,
Vergent Bioscience,
Mnsbir, Inc.,
Invenshure, Llc,
Diamedica Therapeutics Inc.,
Primera Therapeutics.
Mekanistic Therapeutics's categories are Biotechnology Research
Mekanistic Therapeutics's founding year is 2022
